PI3K Hyperactivation Results in Lapatinib Resistance that is Reversed by the mTOR/PI3K Inhibitor NVP-BEZ235

Small molecule inhibitors of HER2 are clinically active in women with advanced HER2 positive breast cancer who have progressed on trastuzumab treatment. However, the effectiveness of this class of agents is limited by either primary resistance or acquired resistance. Using an unbiased genetic approa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Eichhorn, Pieter J.A., Gili, Magüi, Scaltriti, Maurizio, Serra, Violeta, Guzman, Marta, Nijkamp, Wouter, Beijersbergen, Roderick L., Valero, Vanesa, Seoane, Joan, Bernards, René, Baselga, José
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2587064/
https://ncbi.nlm.nih.gov/pubmed/19010894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-08-1740
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars